America’s pharmaceutical research and biotechnology companies understand that accurate information about disease and treatment options makes patients and doctors better partners. And getting that information to patients and consumers is the goal of direct-to-consumer (DTC) pharmaceutical advertising about prescription medicines.
DTC advertising increases people’s awareness of disease and available treatments. Studies show DTC advertising brings patients into their doctors’ offices and starts important doctor-patient conversations about health that might otherwise not take place.
PhRMA’s Guiding Principles on Direct to Consumer Advertising about Prescription Medicines reflect our commitment to improving the educational value of prescription medicine advertisements.
Our DTC Guiding Principles, which were recently revised and strengthened, provide guidance to pharmaceutical research and biotechnology companies on ways to ensure that DTC communications provide accurate, accessible and useful information to patients and consumers. The updated Principles took effect on March 2, 2009.
Affirming its commitment to responsible direct-to-consumer (DTC) pharmaceutical advertising that benefits public health, the PhRMA Board of Directors has adopted measures to strengthen the PhRMA Guiding Principles on Direct to Consumer Advertisements about Prescription Medicines.